Research Article
Clinical Value of Detecting Fecal Calprotectin by Using Colloidal Gold Assay in Screening or Diagnosing Crohn’s Disease
Table 1
Baseline characteristics of patients with CD and the control group.
| | CD patients () | Gastrointestinal dysfunction group
() | Healthy individuals
() |
| | Age in years | | | |
| | Male (%) | 40 (67.8%) | 57 (75%) | 62 (69.7%) |
| | Montreal classification | CD (location) | | | | L1 (ileum): 5 (8.5%) | | | | L2 (colon): 5 (8.5%) | | | | L3 (ileocolon): 43 (72.9%) | | | | L3 + L4 (upper gastrointestinal): 4 (6.7%) | | | | L1 + L4: 2 (3.4%) | | | | CD (behavior) | | | | B1 (inflammatory): 24 (40.7%) | | | | B2 (stricturing): 30 (50.8%) | | | | B3 (fistulating): 5 (8.5%) | | |
| | FCP (μg/g) | >60 (μg/g): 46 (78.0%) | >60 (μg/g): 8 (10.5%) | >60 (μg/g): 1 (1.1%) | | 15-60 (μg/g): 12 (20.3%) | 15-60 (μg/g): 14 (18.4%) | 15-60 (μg/g): 13 (14.6%) | | <15 (μg/g): 1 (1.7%) | <15(μg/g): 54 (71.1%) | <15 (μg/g): 75 (84.3%) |
|
|
|
